Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians Aprajita JagpalJeffrey R. Curtis Review Article 01 February 2018 Pages: 545 - 553
The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies Victoria RotshildLaurent AzoulayIlan Matok Original Research Article 26 February 2018 Pages: 555 - 564
Time Series Disturbance Detection for Hypothesis-Free Signal Detection in Longitudinal Observational Databases Ed WhalenManfred HaubenAndrew Bate Original Research Article 21 February 2018 Pages: 565 - 577
Sorting Through the Safety Data Haystack: Using Machine Learning to Identify Individual Case Safety Reports in Social-Digital Media Shaun ComfortSujan PereraJennifer Fine Original Research Article Open access 14 February 2018 Pages: 579 - 590
A Multi-hospital Before–After Observational Study Using a Point-Prevalence Approach with an Infusion Safety Intervention Bundle to Reduce Intravenous Medication Administration Errors Kumiko O. SchnockPatricia C. DykesDavid W. Bates Original Research Article 06 February 2018 Pages: 591 - 602
Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis Rianne A. WeersinkMargriet BoumaSander D. Borgsteede Original Research Article Open access 12 January 2018 Pages: 603 - 613
The Uncertainty of the Association Between Proton Pump Inhibitor Use and the Risk of Dementia: Prescription Sequence Symmetry Analysis Using a Korean Healthcare Database Between 2002 and 2013 Sun-Kyeong ParkYeon-Hee BaekJu-Young Shin Original Research Article 03 February 2018 Pages: 615 - 624
Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience John F. MarcinakMelvin S. MunsakaNeila Smith Original Research Article 28 February 2018 Pages: 625 - 640
Comment on: “All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population” Tomoyuki Kawada Letter to the Editor 03 May 2018 Pages: 641 - 642
Authors’ Reply to: Tomoyuki Kawada’s Comment on: “All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population’’ Alyssa M. PeckhamKathleen A. FairmanDavid A. Sclar Letter to the Editor 03 May 2018 Pages: 643 - 644